Matching companies load automatically. Browse 24 companies per page; expand filters to narrow the results.
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
74 matching companiesShowing 1–24 / 74
On 2026-05-01, FDA approved vepdegestrant for certain ESR1-mutated ER+/HER2- advanced breast cancers. In August, the company reported completion of a global license to Rigel and expected future data from three Phase 1 programs.
The 2026-10-29 announcement places KT-621 in Phase 2 for AD and asthma and reports Phase 1 healthy-volunteer results for KT-579. Sanofi is advancing KT-485 in Phase 1; Gilead is preparing a KT-200 CDK2 molecular glue IND.
Original Haisco disclosures identify HSK29116 as an oral BTK PROTAC; the NCI Drug Dictionary specifies CRBN recruitment.
Gilead's pipeline updated 2026-10-29 lists GS-6791 as a Phase 1 IRAK4 degrader for inflammatory diseases. Nurix's 2026-10-05 announcement confirms its oral route and clinical status.
An original Phase 1 DKY709 abstract at AACR 2026 describes an oral IKZF2 molecular glue and reports human pharmacodynamic, PK, and preliminary efficacy data through 2024-09-05.
MSD's website records joint clinical development of an MGD candidate with Degron on 2026-05-21. Original MSD / Proxygen announcements describe a multi-target molecular glue collaboration. C4's 2026 SEC filing states that MSD's DAC agreement ended in November 2025.
The website lists DEL/ASMS ligand discovery, linker design, binary / ternary binding, ubiquitination, HiBiT/NanoBRET, and in vivo PK/PD services.
The 2026-10-12 announcement reports the first participant enrolled in Phase 3 DAYBreak CLL-306. NX-5948 is an oral, brain-penetrant BTK degrader. The company also reported collaboration progress with Roche, Gilead, Pfizer, and Sanofi.
AC699 (also called AC0699 on the website) is an oral ERα chimeric degrader. Phase 1 human results and FDA Fast Track were reported in 2024.
A dedicated PROTAC / molecular glue page lists protein production, crystallography, screening, binding kinetics, drug metabolism, bioassays, and AIDD/CADD, plus custom PROTAC design and synthesis.
An April 2026 announcement reports first dosing in Phase 3 setidegrasib/ASP3082 for pancreatic cancer. A Japanese official registry also records first dosing in NSCLC Phase 3 in August 2026.
The company describes AUTAC as comprising an autophagy-recruiting group, target ligand, and linker. Its website does not list named candidates or clinical stages.
The original 2022 study demonstrated the p62-mediated AUTOTAC platform. A 2026 investigator conference abstract still describes IND-enabling preclinical work in neurodegenerative disease.
PAQ develops KRAS degraders. The registered Phase 1 PT0253 study is in advanced solid tumors with KRAS G12D mutations. Historical autophagy positioning was not substituted for current technical disclosures.
The company explicitly supports PROTACs, hydrophobic tags, and molecular glues through FFS, FTE, and integrated discovery models, including target engagement, ubiquitination, proteasome dependence, and bioanalysis.
The 2026-08-11 announcement reports ongoing Phase 2 MOMENTUM and Phase 1b cemsidomide plus elranatamab studies. Phase 1 results were announced in June. A 2026 quarterly report describes other platform collaborations; MSD's DAC agreement ended in November 2025.
The website reports Novartis licensing of the VAV1 molecular glue MRT-6160 and Phase 2 studies. The NEK7 molecular glue MRT-8102 completed Phase 1 GFORCE-1; MRT-2359 is in clinical combination development.
The website defines PLX-61639 as an oral, selective, monovalent SMARCA2 direct degrader and lists its clinical study. PLX-66140 is a CDK2 CRBN molecular glue.
The 2026-02-03 announcement reports first dosing in the Phase 1/2 NEO-811 renal cancer trial. The company pipeline identifies ARNT/HIF-1β as its target and lists pharmaceutical collaborations.
The website describes ORICISION as discovering both protein degraders and conformational correctors, emphasizing patient-derived models and clearance of disease-associated proteins.
AMX-883, first dosed in October 2026, is a DCAF16-mediated BRD9 Targeted Glue. The company previously disclosed collaborations with BMS and Merck KGaA.
An original 2026 ASCO abstract by company researchers describes CT-01 as a GSPT1/NEK7 dual-target molecular glue. Phase 1 began in May 2025, studying monotherapy and combination with everolimus in hepatocellular carcinoma.
The current website focuses on covalent chemistry and ALS / Parkinson's programs. An original 2021 announcement records a four-target Novartis collaboration.
The website describes EPI-326 as a tissue-selective EGFR bispecific antibody degrader in an ongoing Phase 1 NSCLC/HNSCC trial, NCT07462377.
Coverage expands from sourced records; this database does not claim all biopharma companies.
